880 related articles for article (PubMed ID: 35638818)
1. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
[TBL] [Abstract][Full Text] [Related]
2. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
bioRxiv; 2021 Aug; ():. PubMed ID: 34462749
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
[TBL] [Abstract][Full Text] [Related]
4. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
5. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.
Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q
mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428
[TBL] [Abstract][Full Text] [Related]
6. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
7. Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy.
Hoffmann M; Sidarovich A; Arora P; Krüger N; Nehlmeier I; Kempf A; Graichen L; Winkler MS; Niemeyer D; Goffinet C; Drosten C; Schulz S; Jäck HM; Pöhlmann S
mBio; 2022 Jun; 13(3):e0036422. PubMed ID: 35467423
[TBL] [Abstract][Full Text] [Related]
8. Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants.
Wang Q; Ye SB; Zhou ZJ; Li JY; Lv JZ; Hu B; Yuan S; Qiu Y; Ge XY
J Med Virol; 2023 Jan; 95(1):e28116. PubMed ID: 36056469
[TBL] [Abstract][Full Text] [Related]
9. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.
Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
mBio; 2022 Apr; 13(2):e0013522. PubMed ID: 35289643
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
[TBL] [Abstract][Full Text] [Related]
11. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
13. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
Akkız H
Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 evolves to reduce but not abolish neutralizing action.
Zhang Y; Ndzouboukou JB; Lin X; Hou H; Wang F; Yuan L; Gan M; Yao Z; Fu H; Cao J; Fan X
J Med Virol; 2023 Jan; 95(1):e28207. PubMed ID: 36217880
[TBL] [Abstract][Full Text] [Related]
15. Molecular Basis of Mink ACE2 Binding to SARS-CoV-2 and Its Mink-Derived Variants.
Su C; He J; Han P; Bai B; Li D; Cao J; Tian M; Hu Y; Zheng A; Niu S; Chen Q; Rong X; Zhang Y; Li W; Qi J; Zhao X; Yang M; Wang Q; Gao GF
J Virol; 2022 Sep; 96(17):e0081422. PubMed ID: 36000849
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2's Variants of Concern: A Brief Characterization.
Scovino AM; Dahab EC; Vieira GF; Freire-de-Lima L; Freire-de-Lima CG; Morrot A
Front Immunol; 2022; 13():834098. PubMed ID: 35958548
[TBL] [Abstract][Full Text] [Related]
17. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein.
Javanmardi K; Segall-Shapiro TH; Chou CW; Boutz DR; Olsen RJ; Xie X; Xia H; Shi PY; Johnson CD; Annapareddy A; Weaver S; Musser JM; Ellington AD; Finkelstein IJ; Gollihar JD
Cell Host Microbe; 2022 Sep; 30(9):1242-1254.e6. PubMed ID: 35988543
[TBL] [Abstract][Full Text] [Related]
18. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
[TBL] [Abstract][Full Text] [Related]
19. Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1.
Sidarovich A; Krüger N; Rocha C; Graichen L; Kempf A; Nehlmeier I; Lier M; Cossmann A; Stankov MV; Schulz SR; Behrens GMN; Jäck HM; Pöhlmann S; Hoffmann M
Viruses; 2022 Nov; 14(11):. PubMed ID: 36366573
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
